The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Human Coagulation Factor Ⅷ-Global Market Insights and Sales Trends 2025
Synopsis
Human Coagulation Factor Ⅷ is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene result in hemophilia A, an X-linked coagulation disorder Human Coagulation Factor Ⅷ is produced in liver sinusoidal cells and endothelial cells outside the liver throughout the body. This protein circulates in the bloodstream in an inactive form, bound to another molecule called von Willebrand factor, until an injury that damages blood vessels occurs. In response to injury, coagulation factor VIII is activated and separates from von Willebrand factor. The active protein (sometimes written as coagulation factor VIIIa) interacts with another coagulation factor called factor IX. This interaction sets off a chain of additional chemical reactions that form a blood clot.
The global Human Coagulation Factor Ⅷ market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Human Coagulation Factor Ⅷ in various end use industries. The expanding demands from the Hemophilia A and Relvent Bleeding Diseases, are propelling Human Coagulation Factor Ⅷ market. Recombinant Factor VIII, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Human Factor VIII segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human Coagulation Factor Ⅷ, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human Coagulation Factor Ⅷ market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human Coagulation Factor Ⅷ market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human Coagulation Factor Ⅷ sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human Coagulation Factor Ⅷ covered in this report include Bayer, CSL Behring, Baxter, Grifols, Octapharma, Pfizer, Taibang Bio, Shanghai Laishi and Hualan Bio, etc.
The global Human Coagulation Factor Ⅷ market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
CSL Behring
Baxter
Grifols
Octapharma
Pfizer
Taibang Bio
Shanghai Laishi
Hualan Bio
Guangdong Shuanglin
GreenCross
Pfizer
Global Human Coagulation Factor Ⅷ market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human Coagulation Factor Ⅷ market, Segment by Type:
Recombinant Factor VIII
Human Factor VIII
Global Human Coagulation Factor Ⅷ market, by Application
Hemophilia A
Relvent Bleeding Diseases
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Human Coagulation Factor Ⅷ companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Human Coagulation Factor Ⅷ is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene result in hemophilia A, an X-linked coagulation disorder Human Coagulation Factor Ⅷ is produced in liver sinusoidal cells and endothelial cells outside the liver throughout the body. This protein circulates in the bloodstream in an inactive form, bound to another molecule called von Willebrand factor, until an injury that damages blood vessels occurs. In response to injury, coagulation factor VIII is activated and separates from von Willebrand factor. The active protein (sometimes written as coagulation factor VIIIa) interacts with another coagulation factor called factor IX. This interaction sets off a chain of additional chemical reactions that form a blood clot.
The global Human Coagulation Factor Ⅷ market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Human Coagulation Factor Ⅷ in various end use industries. The expanding demands from the Hemophilia A and Relvent Bleeding Diseases, are propelling Human Coagulation Factor Ⅷ market. Recombinant Factor VIII, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Human Factor VIII segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human Coagulation Factor Ⅷ, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human Coagulation Factor Ⅷ market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human Coagulation Factor Ⅷ market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human Coagulation Factor Ⅷ sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human Coagulation Factor Ⅷ covered in this report include Bayer, CSL Behring, Baxter, Grifols, Octapharma, Pfizer, Taibang Bio, Shanghai Laishi and Hualan Bio, etc.
The global Human Coagulation Factor Ⅷ market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
CSL Behring
Baxter
Grifols
Octapharma
Pfizer
Taibang Bio
Shanghai Laishi
Hualan Bio
Guangdong Shuanglin
GreenCross
Pfizer
Global Human Coagulation Factor Ⅷ market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human Coagulation Factor Ⅷ market, Segment by Type:
Recombinant Factor VIII
Human Factor VIII
Global Human Coagulation Factor Ⅷ market, by Application
Hemophilia A
Relvent Bleeding Diseases
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Human Coagulation Factor Ⅷ companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Human Coagulation Factor Ⅷ
1.1 Human Coagulation Factor Ⅷ Market Overview
1.1.1 Human Coagulation Factor Ⅷ Product Scope
1.1.2 Human Coagulation Factor Ⅷ Market Status and Outlook
1.2 Global Human Coagulation Factor Ⅷ Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Human Coagulation Factor Ⅷ Market Size by Region (2018-2029)
1.4 Global Human Coagulation Factor Ⅷ Historic Market Size by Region (2018-2023)
1.5 Global Human Coagulation Factor Ⅷ Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Human Coagulation Factor Ⅷ Market Size (2018-2029)
1.6.1 North America Human Coagulation Factor Ⅷ Market Size (2018-2029)
1.6.2 Europe Human Coagulation Factor Ⅷ Market Size (2018-2029)
1.6.3 Asia-Pacific Human Coagulation Factor Ⅷ Market Size (2018-2029)
1.6.4 Latin America Human Coagulation Factor Ⅷ Market Size (2018-2029)
1.6.5 Middle East & Africa Human Coagulation Factor Ⅷ Market Size (2018-2029)
2 Human Coagulation Factor Ⅷ Market by Type
2.1 Introduction
2.1.1 Recombinant Factor VIII
2.1.2 Human Factor VIII
2.2 Global Human Coagulation Factor Ⅷ Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Human Coagulation Factor Ⅷ Historic Market Size by Type (2018-2023)
2.2.2 Global Human Coagulation Factor Ⅷ Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Human Coagulation Factor Ⅷ Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Human Coagulation Factor Ⅷ Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Human Coagulation Factor Ⅷ Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Human Coagulation Factor Ⅷ Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Human Coagulation Factor Ⅷ Revenue Breakdown by Type (2018-2029)
3 Human Coagulation Factor Ⅷ Market Overview by Application
3.1 Introduction
3.1.1 Hemophilia A
3.1.2 Relvent Bleeding Diseases
3.2 Global Human Coagulation Factor Ⅷ Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Human Coagulation Factor Ⅷ Historic Market Size by Application (2018-2023)
3.2.2 Global Human Coagulation Factor Ⅷ Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Human Coagulation Factor Ⅷ Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Human Coagulation Factor Ⅷ Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Human Coagulation Factor Ⅷ Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Human Coagulation Factor Ⅷ Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Human Coagulation Factor Ⅷ Revenue Breakdown by Application (2018-2029)
4 Human Coagulation Factor Ⅷ Competition Analysis by Players
4.1 Global Human Coagulation Factor Ⅷ Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Coagulation Factor Ⅷ as of 2022)
4.3 Date of Key Players Enter into Human Coagulation Factor Ⅷ Market
4.4 Global Top Players Human Coagulation Factor Ⅷ Headquarters and Area Served
4.5 Key Players Human Coagulation Factor Ⅷ Product Solution and Service
4.6 Competitive Status
4.6.1 Human Coagulation Factor Ⅷ Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Bayer
5.1.1 Bayer Profile
5.1.2 Bayer Main Business
5.1.3 Bayer Human Coagulation Factor Ⅷ Products, Services and Solutions
5.1.4 Bayer Human Coagulation Factor Ⅷ Revenue (US$ Million) & (2018-2023)
5.1.5 Bayer Recent Developments
5.2 CSL Behring
5.2.1 CSL Behring Profile
5.2.2 CSL Behring Main Business
5.2.3 CSL Behring Human Coagulation Factor Ⅷ Products, Services and Solutions
5.2.4 CSL Behring Human Coagulation Factor Ⅷ Revenue (US$ Million) & (2018-2023)
5.2.5 CSL Behring Recent Developments
5.3 Baxter
5.3.1 Baxter Profile
5.3.2 Baxter Main Business
5.3.3 Baxter Human Coagulation Factor Ⅷ Products, Services and Solutions
5.3.4 Baxter Human Coagulation Factor Ⅷ Revenue (US$ Million) & (2018-2023)
5.3.5 Grifols Recent Developments
5.4 Grifols
5.4.1 Grifols Profile
5.4.2 Grifols Main Business
5.4.3 Grifols Human Coagulation Factor Ⅷ Products, Services and Solutions
5.4.4 Grifols Human Coagulation Factor Ⅷ Revenue (US$ Million) & (2018-2023)
5.4.5 Grifols Recent Developments
5.5 Octapharma
5.5.1 Octapharma Profile
5.5.2 Octapharma Main Business
5.5.3 Octapharma Human Coagulation Factor Ⅷ Products, Services and Solutions
5.5.4 Octapharma Human Coagulation Factor Ⅷ Revenue (US$ Million) & (2018-2023)
5.5.5 Octapharma Recent Developments
5.6 Pfizer
5.6.1 Pfizer Profile
5.6.2 Pfizer Main Business
5.6.3 Pfizer Human Coagulation Factor Ⅷ Products, Services and Solutions
5.6.4 Pfizer Human Coagulation Factor Ⅷ Revenue (US$ Million) & (2018-2023)
5.6.5 Pfizer Recent Developments
5.7 Taibang Bio
5.7.1 Taibang Bio Profile
5.7.2 Taibang Bio Main Business
5.7.3 Taibang Bio Human Coagulation Factor Ⅷ Products, Services and Solutions
5.7.4 Taibang Bio Human Coagulation Factor Ⅷ Revenue (US$ Million) & (2018-2023)
5.7.5 Taibang Bio Recent Developments
5.8 Shanghai Laishi
5.8.1 Shanghai Laishi Profile
5.8.2 Shanghai Laishi Main Business
5.8.3 Shanghai Laishi Human Coagulation Factor Ⅷ Products, Services and Solutions
5.8.4 Shanghai Laishi Human Coagulation Factor Ⅷ Revenue (US$ Million) & (2018-2023)
5.8.5 Shanghai Laishi Recent Developments
5.9 Hualan Bio
5.9.1 Hualan Bio Profile
5.9.2 Hualan Bio Main Business
5.9.3 Hualan Bio Human Coagulation Factor Ⅷ Products, Services and Solutions
5.9.4 Hualan Bio Human Coagulation Factor Ⅷ Revenue (US$ Million) & (2018-2023)
5.9.5 Hualan Bio Recent Developments
5.10 Guangdong Shuanglin
5.10.1 Guangdong Shuanglin Profile
5.10.2 Guangdong Shuanglin Main Business
5.10.3 Guangdong Shuanglin Human Coagulation Factor Ⅷ Products, Services and Solutions
5.10.4 Guangdong Shuanglin Human Coagulation Factor Ⅷ Revenue (US$ Million) & (2018-2023)
5.10.5 Guangdong Shuanglin Recent Developments
5.11 GreenCross
5.11.1 GreenCross Profile
5.11.2 GreenCross Main Business
5.11.3 GreenCross Human Coagulation Factor Ⅷ Products, Services and Solutions
5.11.4 GreenCross Human Coagulation Factor Ⅷ Revenue (US$ Million) & (2018-2023)
5.11.5 GreenCross Recent Developments
5.12 Pfizer
5.12.1 Pfizer Profile
5.12.2 Pfizer Main Business
5.12.3 Pfizer Human Coagulation Factor Ⅷ Products, Services and Solutions
5.12.4 Pfizer Human Coagulation Factor Ⅷ Revenue (US$ Million) & (2018-2023)
5.12.5 Pfizer Recent Developments
6 North America
6.1 North America Human Coagulation Factor Ⅷ Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Human Coagulation Factor Ⅷ Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Human Coagulation Factor Ⅷ Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Human Coagulation Factor Ⅷ Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Human Coagulation Factor Ⅷ Market Dynamics
11.1 Human Coagulation Factor Ⅷ Industry Trends
11.2 Human Coagulation Factor Ⅷ Market Drivers
11.3 Human Coagulation Factor Ⅷ Market Challenges
11.4 Human Coagulation Factor Ⅷ Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
